Tarbox Family Office’s Immunovant IMVT Stock Holding History

Tarbox Family Office’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-127	Closed	-$1K	–	1146
2021 Q3	$1K	Buy	+127	New	+$1.15K	﹤0.01%	1058

Other funds holding IMVT

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tarbox Family Office's IMVT Position: Q4 2021 in Review

Tarbox Family Office sold out of Immunovant (IMVT) in Q4 2021, closing a stake of 127 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in IMVT in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 118 funds tracked by Wall St. Rank hold IMVT as of Q4 2021.

Tarbox Family Office reported no remaining Immunovant position as of Q4 2021 after selling out during the quarter.
Tarbox Family Office sold 127 Immunovant shares in Q4 2021, an estimated $1K.
Tarbox Family Office first reported a position in Immunovant in Q3 2021 and held it in 1 quarter.
Tarbox Family Office's Immunovant position peaked at $1K in Q3 2021.
118 funds tracked by Wall St. Rank held Immunovant as of Q4 2021.

Based on Tarbox Family Office's 13F filing for Q4 2021, filed 6 Jan 2022.